Key statistics
On Friday, Waldencast PLC (WALD:NAQ) closed at 1.80, 24.14% above the 52 week low of 1.45 set on Jan 08, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.82 |
|---|---|
| High | 1.82 |
| Low | 1.73 |
| Bid | 1.74 |
| Offer | 1.87 |
| Previous close | 1.80 |
| Average volume | 66.39k |
|---|---|
| Shares outstanding | 128.04m |
| Free float | 53.80m |
| P/E (TTM) | -- |
| Market cap | 230.47m USD |
| EPS (TTM) | -1.80 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Announcements
- Obagi Medical and DermFx Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
- Obagi Medical and Moxie Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
- Obagi Medical Introduces New Lip Therapy Protocol Designed to Resurface, Replenish, and Protect
- Obagi Medical and VIO Med Spa Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
- Obagi Medical and Next Health Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
- UPDATE - Obagi Medical and Alpha Aesthetic Partners Announce Their Collaboration in the ALOHA Program to Drive Real-World Evidence with Obagi® saypha® MagIQ™
- CORRECTION – Obagi Medical and Platinum Dermatology Partners Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
- Obagi Medical Unveils ALOHA Program to Launch Obagi® saypha® MagIQ™ – Pioneering the Largest Real-World Evaluation of a New Hyaluronic Acid Filler
- Waldencast Announces Q2 2025 Results and Provides Q3 2025 Trading Update
- Obagi Medical Shares New Clinical Data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 American Society for Dermatologic Surgery Annual Meeting
More ▼
